Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase 2
NCT02964818 NCT03319712 NCT03656536 |
| gptkbp:clinical_use |
combination therapy
monotherapy |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to pemigatinib |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| https://www.w3.org/2000/01/rdf-schema#label |
Pemazyre
|
| gptkbp:indication |
gptkb:cholangiocarcinoma
|
| gptkbp:ingredients |
gptkb:pemigatinib
|
| gptkbp:label |
black box warning
|
| gptkbp:manufacturer |
gptkb:Incyte_Corporation
|
| gptkbp:marketed_as |
gptkb:2020
|
| gptkbp:mechanism_of_action |
FGFR inhibitor
|
| gptkbp:patient_population |
adults
|
| gptkbp:pharmacokinetics |
oral bioavailability
half-life of 15 hours inhibits FGFR1, FGFR2, and FGFR3 |
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_measures |
liver function tests
complete blood count electrolyte levels |
| gptkbp:side_effect |
gptkb:anemia
gptkb:depression anxiety fatigue muscle pain nausea weight loss abdominal pain fever swelling vomiting diarrhea joint pain dry skin insomnia dehydration constipation dry mouth chills itching skin rash hair loss thrombocytopenia dysgeusia elevated liver enzymes hypophosphatemia hyperphosphatemia stomatitis |
| gptkbp:storage |
room temperature
|
| gptkbp:strength |
4 mg
9 mg |
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
treatment of certain types of cancer
|
| gptkbp:bfsParent |
gptkb:INCY
gptkb:Incyte |
| gptkbp:bfsLayer |
6
|